Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020–January 2021

Manoj V. Murhekar a,*, Tarun Bhatnagar a, Jeromie Wesley Vivian Thangaraj a, V. Saravanakumar a, Muthusamy Santosh Kumar a, Sriram Selvaraju b, Kiran Rade c, C.P. Girish Kumar a, R. Sabarinathan a, Alka Turuk d, Smita Asthana e, Rakesh Balachandar f, Sampada Dipak Bangar g,h, Avi Kumar Bansal i,j, Vishal Chopra i,j, Dasarathi Das k, Alok Kumar Deb l,m, Kangiam Rekha Devi l,m, Vikas Dhikav m,n, Gaurav Raj Dwivedi o,p, S. Muhammad Salim Khan o,q, M. Sunil Kumar r, Avula Laxmaiah s,t,u, Major Madhukar v,w, Amarendra Mahapatra x,y, Chethana Rangaraju z, Jyotirmayee Turuk z, Rajiv Yadav a,n,o, Rushikesh Andhalkar b, K. Arunraj a, Dinesh Kumar Bharadwaj q,r,s, Pravin Bharti t,u, Debdupta Bhattacharya t,u, Jyothi Bhat a, Ashrafjit S. Chahal a,t, Debjit Chakraborty k,l, Anshuman Chaudhury l,m, Hirawati Devai n, Sarang Dhatra o,p, Rakesh Dayal u,v, D. Elantamilan m,p, Prathiksha Girdharan b, Inaamul Haq s,t, Ramesh Kumar Hudda u,v, Babu Jagjeevan n,q,r, Arshad Kallith a,t, Srikantha Kanungo s, Nivethitha N. Krishnan a, Jaya Singh Kshatri s,t,u, V.G. Vinoth Kumar b, G.G.J. Naga Lakshmi v, Ganesh Mehta h, Nandan Kumar Mishra a, Anindya Mitra u,v, K. Nagbhushanam b, Arlappa Nimmathota q,v, A.R. Nirmala s,v, Ashok Kumar Pandey n, Ganta Venkata Prasad v, Mariya Amin Qureshi n,v, Sirasanambatti Devaraju Reddy h, Abu Robinson b, Seema Sahay s,t, Rochak Saxena w, Kritthiaka Sekar b, Vijay Kumar Shukla v,w, Hari Bhan Singh h, Prashant Kumar Singh e, Pushpendra Singh l,m, Rajeev Singh n, Nivetha Srivinasa b, Dantuluri Sheethal Varma v,w, Ankit Viramgami f, Vimith Cheruvathoor Wilson b, Surabhi Yadav b, Suresh Yadav s,t, Kamran Zaman s,t, Amit Chakrabarti f,t, Aparup Das s,t, R.S. Dhaliwala m,n,s, Shanta Dutta k,l,m, Rajni Kant a,b, A.M. Khan d,f, Kanwar Narain a,b, Somashekar Narasimhaiah a,b, Chandrasekaran Padmapriyadarshini b, Krishna Pandey t, Sanghamitra Pati a,b, Shripad Patil b, Hemalatha Rajkumar a,b, Tekumalla Ramaraov a,b, Y.K. Sharma w,z, Shalini Singh s,z, Samiran Panda d, D.C.S. Reddy z, Balram Bhargava d, on behalf of ICMR Serosurveillance Group

ICMR National Institute of Epidemiology, Chennai, Tamil Nadu, India
b ICMR National Institute of Research in Tuberculosis, Chennai, Tamil Nadu, India
c WHO Country Office for India, New Delhi, India
d Indian Council of Medical Research, New Delhi, India

* Corresponding author at: ICMR National Institute of Epidemiology, Chennai 600077, India.
E-mail address: mmurhekar@nicemr.org.in (M.V. Murhekar).

1 Authors in alphabetical order, contributed equally.
2 Authors in alphabetical order, contributed equally.
3 Authors in alphabetical order, contributed equally.

* ICMR Serosurveillance Group. Epidemiology and Surveillance Working Group: Tanu Anand, Giridhara R. Babu, Himanshu Chauhan, Tanzin Dikid, Raman R. Gangakhedkar, Shashi Kant, Sanket Kulkar, J.P. Muliyil, Ravindra Mohan Pandey, Swarup Sarkar, Naman Shah, Aakash Shrivistava, Sujeet K. Singh and Sanjay Zodpey. Laboratory and Data Management Team: Anusha Hindupur, P.R. Asish, M. Chellakumar, D. Chokkalingam, Sauvik Dasgupta, M.M.E. Gowtham, Annamma Jose, K. Kalayarseni, N.N. Karthik, T. Karunakaran, K. Kiruthika, H. Dinesh Kumar, S. Sarath Kumar, M.P. Sarath Kumar, E. Michaelraj, Josephine Pradhan, E.B. Arun Prasath, D. Gladys Angelin Rachel, Sudha Rani, Amanda Rozario, R. Sivakumar, P. Gnaana Soundari, K. Sujeetha and Aarya Vinod.

https://doi.org/10.1016/j.ijid.2021.05.040
1201-9712/© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Background: Earlier serosurveys in India revealed seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) of 0.73% in May–June 2020 and 7.1% in August–September 2020. A third serosurvey was conducted between December 2020 and January 2021 to estimate the seroprevalence of SARS-CoV-2 infection among the general population and healthcare workers (HCWs) in India.

Methods: The third serosurvey was conducted in the same 70 districts as the first and second serosurveys. For each district, at least 400 individuals aged ≥10 years from the general population and 100 HCWs from subdistrict-level health facilities were enrolled. Serum samples from the general population were tested for the presence of immunoglobulin G (IgG) antibodies against the nucleocapsid (N) and spike (S1-RBD) proteins of SARS-CoV-2, whereas serum samples from HCWs were tested for anti-S1-RBD. Weighted seroprevalence adjusted for assay characteristics was estimated.

Results: Of the 28,598 serum samples from the general population, 4585 (16%) had IgG antibodies against the N protein, 6647 (23.2%) had IgG antibodies against the S1-RBD protein. Serum samples from 2001 HCWs were tested for anti-S1-RBD. Weighted and assay-characteristic-adjusted seroprevalence against either antibody was 24.1% (95% confidence interval (CI) 23.0–25.3%). Among 7385 HCWs, the seroprevalence of anti-S1-RBD IgG antibodies was 25.6% (95% CI 23.5–27.8%).

Conclusions: Nearly one in four individuals aged ≥10 years from the general population as well as HCWs in India had been exposed to SARS-CoV-2 by December 2020.

© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Population-based serosurveys are recommended to estimate the proportion of a population already infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Repeated cross-sectional serosurveys conducted in the same geographical location provide estimates to monitor trends over a period of time (World Health Organization, 2020a). Information from repeated cross-sectional surveys is valuable for public health decision makers to design and revise containment strategies. A meta-analysis undertaken by Chen et al. (2021) estimated that the overall global seroprevalence of SARS-CoV-2 was 8.0% in the general population and 17.1% among healthcare workers (HCWs).

With more than 10 million laboratory-confirmed cases and nearly 150,000 reported deaths as of 31 December 2020, India has the second highest reported number of cases of coronavirus disease 2019 (COVID-19) globally (World Health Organization, 2020b). The nationwide lockdown imposed between March and May 2020 in India was relaxed in a phased manner from June 2020, allowing interstate and interdistrict movement of people as well as restoration of economic activities (Ministry of Home Affairs, Government of India, 2020, 2021). Two population-based serial serosurveys conducted in 70 Indian districts indicated that the prevalence of SARS-CoV-2 infection among adults had increased 10-fold, from 0.73% [95% confidence interval (CI) 0.34–1.13%] in May–June 2020 to 7.1% (95% CI 6.2–8.2%) in August–September 2020 (Murhekar et al., 2020, 2021). The number of infections per reported COVID-19 case decreased from 81.6–130.1 in May–June 2020 to 26–32 in August–September 2020, mainly due to improvements in testing capacity and the number of tests performed in the country (Murhekar et al., 2020, 2021).

SARS-CoV-2 poses a high occupational risk to HCWs, who are at the forefront of management of COVID-19 cases in hospital settings. Knowledge of the burden of infection among HCWs is important to gauge the risk of within and outside hospital transmission of SARS-CoV-2, and evaluate in-hospital infection control practices and adherence to non-pharmaceutical interventions (Piccoli et al., 2021).

The number of cases of COVID-19 in India has shown a downward trend since mid-September 2020, with the reported number of cases declining from more than 90,000 per day in September 2020 to less than 20,000 cases per day in December 2020. This declining trend has been seen in all Indian states, except Kerala (FETP Network – Chennai, India, 2021). In this context, the authors conducted a third nationwide serosurvey between December 2020 and January 2021 to estimate the seroprevalence of SARS-CoV-2 antibodies in the general population, and determine the trends in infection since the previous serosurveys. In
addition, seroprevalence was estimated among HCWs working in subdistrict-level public health facilities.

**Methods**

**Survey of general population**

The third serosurvey followed the same methodology as the first and second nationwide serosurveys (Murhekar et al., 2020, 2021) (see online Supplementary material). Briefly, the third population-based serosurvey was conducted in the same 700 clusters (villages in rural areas and wards in urban areas) from 70 districts selected at random across India as in the first two serosurveys. The authors aimed to select a minimum of 400 individuals aged ≥10 years from each district, with a total sample size of 28,000 individuals (see online Supplementary material). The survey teams first selected four random locations from each cluster. Starting from a random household in each location, contiguous households were visited. All household members aged ≥10 years who were permanent residents in the area were enumerated, and consenting individuals present at the time of the visit of the survey team were included in the survey. No additional visits were made to include households which were locked or household members who were not present at the time of the first visit. In order to select at least 40 individuals from each cluster, the field teams visited a minimum of four households from each of the four random points, and enrolled at least 10 individuals per random starting location. If the teams did not identify 10 eligible individuals from the four households, more households were visited. The survey was conducted between 18 December 2020 and 6 January 2021.

**Survey of HCWs**

Two to three subdistrict-level public health facilities (e.g., ‘taluk’ or subdivisional hospital, community or primary health centre) closest to the selected cluster/s for the household survey were selected from each of the 70 districts identified for the general population survey. All consenting individuals working in these facilities were included to ensure participation of ≥100 HCWs from each district.

**Data collection**

Eligible individuals from the general population and HCWs who consented to participate were interviewed using the Open Data Kit mobile application (https://opendatkit.org/) to collect information on sociodemographic details, history of symptoms suggestive of COVID-19 since March 2020 (e.g., fever, cough, shortness of breath, sore throat, new loss of taste or smell, fatigue), contact with laboratory-confirmed COVID-19 cases, and history of COVID-19 illness. Venous blood (3–5 mL) was collected from each participant, and centrifuged serum samples were transported to ICMR National Institute of Epidemiology, Chennai under cold chain conditions.

**Laboratory investigations**

Serum samples collected from individuals from the general population were tested for the presence of immunoglobulin G (IgG) antibodies against SARS-CoV-2 on the Advia Centaur Immunoassay system using the Siemens SARS-CoV-2 IgG assay (Siemens Healthineers, India, Mumbai) and Abbott Architect i2000SR automated analyser using the Abbott SARS-CoV-2 IgG assay (Abbott Park, IL, USA). The Siemens assay detects IgG antibodies against the spike protein of the receptor binding domain (S1–RBD), and the Abbott assay detects IgG antibodies against the nucleocapsid (N) protein of SARS-CoV-2. Serum samples from HCWs were tested only for IgG antibodies against the S1–RBD protein. Sensitivity and specificity of the Siemens IgG assay are 100% and 99.90% respectively, compared with 100% and 99.6% for the Abbott IgG assay (Center for Devices and Radiological Health, 2021). Serum samples with cut-off indices (COI) ≥1.0 on the Siemens IgG assay or ≥1.4 on the Abbott IgG assay were considered as positive for IgG antibodies against SARS-CoV-2. One hundred and fifty positive serum samples and 150 negative serum samples for each assay were retested for quality control purposes.

**Statistical analysis**

The characteristics of study participants are described as percentage, mean and standard deviation (SD). The reported occupations were categorized as high risk and low risk on the basis of the potential risk of exposure to a known or unknown COVID–19 case. For example, occupations such as HCWs, police or security personnel, shopkeepers, bus or taxi drivers, and bank employees were considered as high-risk occupations; and farmers, retired employees, students, information technology professionals and homemakers were considered as low-risk occupations (Murhekar et al., 2021). The weighted seroprevalence of IgG antibodies against the N protein and the S1–RBD protein were estimated separately, along with 95% CI, using a random-effects model to account for cluster sampling. Sampling weights were calculated as the product of the inverse of the sampling fraction for the selection of districts and the selection of villages or wards from each district. Weighted seroprevalence was further adjusted for the sensitivity and specificity of the respective assays (Semos and Tian, 2021). Overall seroprevalence in the general population was estimated by considering serum samples positive on any of the assays. Weighted overall seroprevalence was adjusted for joint sensitivity and specificity of the two assays (Semos and Tian, 2021). Seroprevalence among HCWs was considered on the basis of the anti-S1 assay alone. In addition, overall seroprevalence was calculated by age group, sex, area of residence and COVID-19-related characteristics of the study participants.

The first serosurvey was conducted among adults alone, whereas individuals aged ≥10 years were surveyed in the second and third surveys. The serum samples in the second serosurvey were tested only for IgG antibodies against the N protein using the Abbott assay. For comparison of seroprevalence in the three surveys, one adult per household was selected at random from the survey database, and adjusted seroprevalence of IgG antibodies against the N protein was estimated among these adults.

Overall adjusted seroprevalence in the general population aged ≥10 years was applied to the total population of the entire country aged ≥10 years to estimate the total number of cases of SARS-CoV-2 infection. Studies indicate that IgG antibodies start appearing between 7 and 14 days after symptom onset and reverse transcriptase polymerase chain reaction (RT-PCR) positivity (Long et al., 2020). The infection to case ratio was estimated by dividing the estimated number of SARS-CoV-2 infections by the number of reported COVID-19 cases detected by RT-PCR or rapid antigen test 1 week (19 December 2020) and 2 weeks (12 December 2020) before the median survey date (26 December 2020).

**Sensitivity analysis**

IgG antibodies against SARS-CoV-2 infection decline over time (Ripperger et al., 2020; Bolotin et al., 2021). The COI for different assays specified by manufacturers are based on ≥14 days convalescent sera. Lowering the COIs could improve the sensitivity of the assays used for population-based serosurveys (Bolotin et al.,...
In this study, seroprevalence was also calculated using lower COI of >0.54 for the Abbott assay and 0.32 for the Siemens IgG assay, as suggested by Irsara et al. (2021). In addition, seroprevalence was estimated using the lowest values of sensitivity (90.8% for the Abbott assay and 78.8% for the Siemens assay) and specificity (99.3% for Abbott assay and 100% for the Siemens assay) estimated through external validation studies (see online Supplementary material).

Protection of human participants

Written informed consent was obtained from individuals aged ≥18 years, and assent was obtained from children aged between 10 and 17 years, with written informed consent from their parents or guardians, before the survey (Indian Council of Medical Research, 2017). The Institutional Human Ethics Committee of ICMR National Institute of Epidemiology, Chennai approved the study protocol.

Results

Seroprevalence among the general population

In total, 17,178 households from 700 clusters in 70 districts were visited. Of the 35,099 individuals who were available at the time of the visit of the survey teams, 28,598 (81.5%) consented to participate (Figure 1).

The mean age of the study participants was 38.2 (SD 16.4) years. Nearly three-quarters of the participants (n = 21,187, 74.1%) were residing in rural areas, 51.6% (n = 14,763) were female, and 15.2% (n = 4333) had an occupation with a higher risk of exposure to potentially infected persons. Of the 1889 (6.6%) participants who reported history of COVID-19 symptoms since March 2020, 474 (25.1%) reported seeking medical care. The main symptoms reported by participants were cough (63.7%), fever (52.4%), tiredness/fatigue (13%), sore throat (12.4%), shortness of breath (11.2%), new loss of smell (4.2%) and new loss of taste (3.5%) (see online Supplementary material). In total, 3232 (11.4%) individuals reported having been tested for SARS-CoV-2 by RT-PCR or rapid antigen test in the past, of whom 287 (8.9%) reported a positive result (Table 1).

Of the 28,598 individuals tested, 4585 (16%) had IgG antibodies against the N protein and 6647 (23.2%) had IgG antibodies against the S1-RBD protein. Weighted and assay-characteristic-adjusted seroprevalence of IgG antibodies against the N and S1-RBD proteins were 14.3% (95% CI 13.6–15.0%) and 21.5% (95% CI 20.4–22.6%), respectively. Overall, 7436 individuals had IgG antibodies against either the N protein or the S1-RBD protein, with weighted and assay-characteristic-adjusted seroprevalence of 24.1% (95% CI 23.0–25.3%) (Table 2). Seroprevalence in districts ranged between 4.9% (20/407) in Mahisagar (Gujarat) and 44.4% (176/396) in Bijapur (Chhattisgarh) (see online Supplementary material).

Overall seroprevalence did not differ by sex (males 23.2%, 95% CI 22.1–24.5%; females 24.9%, 95% CI 23.7–26.3%). Seroprevalence was lowest among individuals aged 18–44 years and was similar among other age groups. Individuals residing in rural areas had significantly lower seroprevalence (21.4%, 95% CI 20.3–22.6%) compared with those living in urban non-slum areas (29.5%, 95% CI 27.0–32.1%) and urban slum areas (34.7%, 95% CI 31.2–38.5%) (Table 3, see online Supplementary material).

Seropositivity was higher among individuals who reported COVID-19-related symptoms (28.7%, 95% CI 26.1–31.4%), and had contact with COVID-19 cases, either within (42.5%, 95% CI 36.7–48.3%) or outside (24.9%, 95% CI 20.0–30.6) the household.

Of the 287 individuals who reported COVID-19 infection by rapid antigen test or RT-PCR, 178 (63.6%, 95% CI 57.2–69.4%) were seropositive (Table 3). Seropositivity had a positive non-linear correlation with the cumulative incidence of reported COVID-19 cases in the 70 districts (correlation coefficient 0.352) (see online Supplementary material).

Seroprevalence among adults

In order to compare seroprevalence among adults between the three serosurveys, 16,565 adults, one per household, were selected at random from the database. Of these, 2657 had IgG antibodies against the N protein with weighted and adjusted seroprevalence of 14.3% (95% CI 13.5–15.1%). The weighted seroprevalence of IgG antibodies against either the N protein or the S-RBD protein was 24.3% (95% CI 23.1–25.6%).

Burden of SARS-CoV-2 infection in December 2020

Applying the overall seroprevalence to the population aged ≥10 years, it was estimated that 271,404,207 (95% CI 259,016,464–284,918,110) individuals in India had been infected by December 2020. With 10,027,311 and 10,181,165 COVID-19 cases reported by 12 December and 19 December 2020, respectively, it was estimated that there were 27.1 (95% CI 25.8–28.4) and 26.7 (95% CI 25.4–28.0) infections per reported case of COVID-19 (Table 4).

Sensitivity analysis

Using the lower cut-off values, the overall seroprevalence of SARS-CoV-2 infection was 37.4% (95% CI 35.9–38.8) (see online Supplementary material). Considering the lowest values of
Table 1
Characteristics of study participants.

| Characteristics                                | General population n (%) | Healthcare workers n (%) |
|------------------------------------------------|--------------------------|--------------------------|
| Age (years)                                    | 28,598                   | 7385                     |
| 10–17                                          | 2290 (8.0)               | –                        |
| 18–44                                          | 16,333 (57.1)            | 5351 (72.5)              |
| 45–60                                          | 6038 (24.3)              | 1956 (26.4)              |
| >60                                            | 3037 (10.6)              | 78 (11)                  |
| Mean age (SD)                                  | 38.2 (16.4)              | 38.0 (10.2)              |
| Sex                                            |                          |                          |
| Male                                           | 13,817 (48.3)            | 3175 (43.0)              |
| Female                                         | 14,763 (51.6)            | 4206 (56.9)              |
| Other                                          | 18 (0.1)                 | 4 (0.1)                  |
| Residence                                      |                          |                          |
| Rural                                          | 21,187 (74.1)            | –                        |
| Urban non-slum                                 | 4621 (16.9)              | –                        |
| Urban slum                                     | 2590 (9.0)               | –                        |
| Type of healthcare worker                      |                          |                          |
| Doctors/nurses                                 | –                        | n = 7382                 |
| Paramedical staff                              | –                        | 2014 (27.3)              |
| Field staff                                    | –                        | 2684 (36.4)              |
| Admin staff                                    | –                        | 2031 (27.5)              |
| COVID-19 related symptoms                     |                          |                          |
| History of COVID-19 symptoms since March 2020 | 1889 (6.6)               | 1066 (14.4)              |
| Medical care sought by symptomatic cases       | 474/1889 (25.1)          | 557/1066 (52.3)          |
| History of hospitalization                    | 73/474 (15.4)            | 173/577 (31.1)           |
| Occupation                                     | n = 28575                | –                        |
| High risk of exposure to COVID-19             | 4333 (15.2)              | –                        |
| History of contact with known COVID-19 case   | n = 28,576               | –                        |
| Within household                               | 598 (2.1)                | –                        |
| Outside household                              | 297 (1.0)                | –                        |
| No history of contact with known COVID-19 case| 27,681 (96.9)            | –                        |
| History of contact with known COVID-19 case   | –                        | n = 7382                 |
| Health facility                                | –                        | 3120 (42.3)              |
| Within household                               | –                        | 130 (1.8)                |
| Outside health facility/household             | –                        | 191 (2.6)                |
| No history of contact with known COVID-19 case| –                        | 3941 (53.3)              |
| Ever tested for COVID-19                      | n = 28,598               | n = 7385                 |
| RT-PCR                                         | 1028 (3.6)               | 1663 (22.5)              |
| Rapid antigen test                             | 1477 (5.2)               | 1509 (20.4)              |
| RT-PCR and rapid antigen test                 | 330 (1.2)                | 1402 (19.0)              |
| Don’t know the type of test                   | 397 (1.4)                | 126 (1.7)                |
| Not tested for COVID-19                       | 25,366 (88.6)            | 2685 (36.4)              |
| Results of COVID-19 testing                   | n = 3232                 | n = 4700                 |
| Reported positive for COVID-19                | 287 (8.9)                | 664 (14.1)               |

SD, standard deviation; COVID-19, coronavirus disease 2019; RT-PCR, reverse transcriptase polymerase chain reaction.

Table 2
Seroprevalence (%) of immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus-2 infection, India, August–September 2020.

| General population aged ≥10 years | Healthcare workers |
|-----------------------------------|--------------------|
| Anti-N antibodies                 | Anti-S1-RBD antibodies | Anti-N or anti-S5 antibodies | Anti-S1-RBD antibodies |
| Number of individuals tested      | 28,598              | 28,598                       | 28,598                  | 7385                     |
| Number of positives              | 4585                | 6647                         | 7436                    | 1899                     |
| Unweighted prevalence\(^\circ\)  | 16.0 (15.3–16.8)    | 23.2 (22.2–24.3)             | 26.0 (25.0–27.1)        | 25.7 (23.7–27.9)         |
| Weighted prevalence\(^\circ\)    | 14.6 (13.9–15.3)    | 21.7 (20.6–22.8)             | 24.6 (23.5–25.7)        | –                       |
| Adjusted prevalence\(^\circ\)    | 14.3 (13.6–15.0)    | 21.5 (20.4–22.6)             | 24.1 (23.0–25.3)        | 25.6 (23.5–27.8)         |

N, nucleocapsid protein; S1-RBD, spike protein of the receptor binding domain.
\(^\circ\) Adjusted for clustering.
\(^\circ\) Weighted for sampling weights.
\(^\circ\) Adjusted for test performance.

Sensitivity and specificity obtained from external validation studies, the overall seroprevalence was 24.5% (95% CI 23.4–25.7).

Seroprevalence among HCWs

In total, 7385 individuals working in 199 subdistrict-level public health facilities in 70 districts were included in the survey. Their mean age was 38 (SD 10.2) years and 4206 (56.9%) were female. Approximately one third (n = 2684, 36.4%) were paramedical workers and 27.3% (n = 2014) were doctors/nurses (Table 1). Overall, 1066 (14.4%) reported a history of COVID-19 symptoms since March 2020, and 3441 (46.7%) reported exposure to a case of COVID-19. In all, 664 (14.1%) of the 4700 individuals who reported COVID-19 testing by rapid antigen testing or RT-PCR were positive (Table 1).

Test-performance-adjusted seroprevalence of IgG antibodies against SARS-CoV-2 infection was 25.7% (95% CI 23.7–27.9) (Table 2). Seroprevalence did not differ between different HCW...
Table 3
Seroprevalence (%) of immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus-2 infection by demographic characteristics, India, December 2020–January 2021.

| Characteristics                  | General population aged ≥ 10 years (n = 28,598) | Healthcare workers (n = 7385) |
|----------------------------------|-------------------------------------------------|------------------------------|
|                                  | No. tested | No. positive (anti-N/anti-S1-RBD antibodies) | Weighted and test-performance-adjusted seroprevalence % (95% CI) | No. tested | No. positive (only S1-RBD) | Test-performance-adjusted seroprevalence % (95% CI) |
| Sex                              |            |                                           |                        |            |                             |                                              |
| Male                             | 13,817     | 3503                                      | 23.2 (22.1–24.5)       | 3175       | 810                          | 25.4 (23.5–27.3)                              |
| Female                           | 14,763     | 3928                                      | 24.9 (23.7–26.3)       | 4206       | 1089                         | 25.8 (23.0–28.7)                              |
| Other                            | 18         | 5                                         |                         | 4          | 0                            | –                                             |
| Age (years)                      |            |                                           |                        |            |                             |                                              |
| 10–17                            | 2290       | 634                                       | 27.2 (24.9–29.4)       | –          | –                            | –                                             |
| 18–44                            | 16,333     | 3936                                      | 22.2 (21.1–23.4)       | 5351       | 1295                         | 24.0 (21.9–26.3)                              |
| 45–60                            | 6938       | 2011                                      | 26.7 (25.2–28.2)       | 1956       | 587                          | 29.9 (27.1–32.9)                              |
| >60                              | 3037       | 855                                       | 26.3 (24.3–28.3)       | 78         | 17                           | 21.6 (13.8–32.2)                              |
| Area of residence                |            |                                           |                        |            |                             |                                              |
| Rural                            | 21,187     | 4997                                      | 21.4 (20.3–22.6)       | –          | –                            | –                                             |
| Urban non-slum                   | 4821       | 1520                                      | 29.5 (27.0–32.1)       | –          | –                            | –                                             |
| Urban slum                       | 2590       | 919                                       | 34.7 (31.2–38.5)       | –          | –                            | –                                             |
| Occupation with high risk of exposure to COVID-19 |            |                                           |                        |            |                             |                                              |
| Yes                              | 4333       | 1036                                      | 21.7 (20.1–23.3)       | –          | –                            | –                                             |
| No                               | 24,242     | 6391                                      | 24.5 (23.4–25.8)       | –          | –                            | –                                             |
| Type of healthcare worker        |            |                                           |                        |            |                             |                                              |
| Doctors/nurses                   | –          | –                                         | –                      | 2014       | 537                          | 26.6 (23.5–29.7)                              |
| Paramedical staff                | –          | –                                         | –                      | 2684       | 681                          | 25.3 (22.8–27.9)                              |
| Field staff                      | –          | –                                         | –                      | 2031       | 518                          | 25.4 (22.5–28.4)                              |
| Admin staff                      | –          | –                                         | –                      | 653        | 162                          | 24.6 (20.5–29.4)                              |
| History of COVID-19-related symptoms since 1 March 2020 |            |                                           |                        |            |                             |                                              |
| Yes                              | 1889       | 651                                       | 28.7 (26.1–31.4)       | 1066       | 407                          | 38.1 (32.9–43.5)                              |
| No                               | 26,709     | 6785                                      | 23.8 (22.7–24.9)       | 6319       | 1482                         | 23.4 (21.4–25.7)                              |
| History of contact with a known COVID-19 case |            |                                           |                        |            |                             |                                              |
| Within household                 | 598        | 225                                       | 42.5 (36.7–48.3)       | –          | –                            | –                                             |
| Outside household                | 297        | 96                                        | 24.9 (20.0–30.6)       | –          | –                            | –                                             |
| No                               | 23,221     | 5850                                      | 23.4 (22.3–24.5)       | –          | –                            | –                                             |
| Don’t know                       | 4460       | 1256                                      | 25.6 (23.4–27.8)       | –          | –                            | –                                             |
| History of contact with a known COVID-19 case |            |                                           |                        |            |                             |                                              |
| Health facility                  | –          | –                                         | –                      | 3120       | 864                          | 27.6 (24.8–30.4)                              |
| Within household                 | –          | –                                         | –                      | 130        | 46                           | 35.3 (26.7–44.9)                              |
| Outside health facility/ household | –         | –                                         | –                      | 191        | 57                           | 29.7 (21.3–39.7)                              |
| No                               | –          | –                                         | –                      | 3255       | 751                          | 22.9 (20.2–25.9)                              |
| Don’t know                       | –          | –                                         | –                      | 686        | 180                          | 26.1 (22.9–29.5)                              |
| Previously tested for COVID-19   |            |                                           |                        |            |                             |                                              |
| RT-PCR                           | 1028       | 357                                       | 29.0 (25.9–32.2)       | 1663       | 477                          | 28.6 (25.2–32.2)                              |
| Rapid antigen test               | 1477       | 485                                       | 26.5 (23.6–29.6)       | 1509       | 415                          | 27.4 (23.7–31.3)                              |
| RT-PCR and rapid antigen test    | 330        | 123                                       | 29.6 (24.5–35.1)       | 1402       | 386                          | 27.4 (23.8–31.3)                              |
| Don’t know the type of test      | 397        | 128                                       | 20.3 (15.6–26.2)       | 126        | 23                           | 18.1 (13.2–24.1)                              |
| Not tested                       | 25,344     | 6334                                      | 23.8 (22.7–24.9)       | 2682       | 597                          | 22.1 (19.7–24.7)                              |
| Results of COVID-19 testing      |            |                                           |                        |            |                             |                                              |
| Reported positive for COVID-19   | 287        | 178                                       | 63.6 (57.2–69.4)       | 664        | 395                          | 59.4 (54.0–64.6)                              |
| Reported negative for COVID-19   | 2526       | 778                                       | 27.6 (25.2–30.2)       | 3982       | 900                          | 22.4 (20.0–25.1)                              |
| Don’t know                       | 419        | 137                                       | 30.8 (25.3–36.8)       | 54         | 6                            | 30.9 (4.2–25.4)                               |

CI, confidence interval; COVID-19, coronavirus disease 2019; RT-PCR, reverse transcriptase polymerase chain reaction; N, nucleocapsid protein; S1-RBD, spike protein of the receptor binding domain.
categories. Seroprevalence did not differ by age and sex. Seroprevalence was higher among HCW who reported COVID-19 symptoms in the past, those who reported contact with a COVID-19 case within the household, and those who reported a positive result on rapid antigen testing or RT-PCR (Table 3).

### Discussion

The findings of the third serosurvey indicate that nearly 24% of India’s population aged ≥10 years had been exposed to SARS-CoV-2 infection by December 2020, with an estimated 271 million infections. Seroprevalence did not differ by sex, but was lower among adults aged 18–44 years and in rural areas compared with urban areas. The results also indicate that approximately one-quarter of HCWs working in the peripheral public sector health facilities were positive for IgG antibodies.

Antibody assays were used to detect IgG against the N and S1-RBD proteins of SARS-CoV-2 in this survey. N-protein assays are reported to be more sensitive than S1 assays for the detection of antibodies in mildly infected patients that are reported to show absent or delayed, and lower SARS-CoV-2 antibody responses (Ozçürümez et al., 2020; van Tol et al., 2020). It has been shown that the anti-N antibodies appear earlier than the S antibodies, and may therefore increase the clinical sensitivity of the assay if samples are drawn early (Rikhtegar Tehrani et al., 2020). In the third serosurvey, 800 individuals were reactive for the N-protein but negative for the S1-RBD protein, possibly suggesting early infections. The IgG antibody response against different viral antigens is heterogeneous in nature and the results do not always correlate with each other (McAndrews et al., 2020). Therefore, the detection of antibodies against two different antigens, with high sensitivity and specificity, is needed to confirm the findings and avoid false-negative results in surveillance studies (Irsara et al., 2021).

Seroprevalence studies provide information about the extent of transmission in the past, and help predict the future course of the pandemic (World Health Organization, 2020a; Chen et al., 2021). Seroprevalence of IgG antibodies against SARS-CoV-2 among individuals aged ≥10 years in India increased from 6.6% in August 2020 to 24.1% in December 2020. The prevalence of IgG antibodies against the N protein between the two serosurveys increased at least 2.2-fold. Serum samples from the previous serosurvey were not tested for anti-S1-RBD IgG antibodies. During the same period, the reported number of COVID-19 cases in India has increased 3.5-fold. Anti-N antibody seropositivity has decreased in 15 of the 70 survey districts by 10.7% to 63.4%, with the steepest decline in Vizianagram (Andhra Pradesh), Chennai (Tamil Nadu) and Ganjam (Odisha) districts. In the remaining 55 districts, seropositivity to anti-N antibodies has increased 1.04–76-fold (see online Supplementary material). This increase in seroprevalence is consistent with the increase in the number of COVID-19 cases reported between August and December 2020 in these districts (see online Supplementary material).

In the third serosurvey, seroprevalence was significantly lower in the 18–44 years age group, whereas in the second serosurvey, prevalence was similar across age groups. Between August and December 2020, the age-specific seroprevalence of anti-N antibodies increased 1.8-fold among individuals aged 18–44 years and 2.6–3.1-fold in the remaining age groups (see online Supplementary material).

Lower seroprevalence in the active and productive age group compared with other age groups is not consistent with the transmission pattern of COVID-19. This age group was exposed to infection early in the pandemic, as reflected by the relatively high incidence of COVID-19 among this age group between January and April 2020 (ICMR COVID Study Group, 2020). Therefore, the lower seroprevalence found in this age group could be due to relatively higher waning of IgG antibodies compared with other age groups. It is noteworthy that 81% of individuals with RT-PCR-confirmed infection were seropositive during the second survey, compared with 63% during the third serosurvey.

Higher seroprevalence of SARS-CoV-2 infection was found in urban areas compared with rural areas in the third serosurvey. Although this pattern was similar to the second serosurvey in August 2020, seroprevalence did not differ between slum and non-slum urban areas, as was observed in August 2020. Between August and December 2020, the increase in seroprevalence was highest in rural areas (2.5-fold), followed by urban non-slum areas (1.93-fold) and urban slum areas (1.07-fold), reflecting the varied distribution of susceptible populations in these areas. The declining trend in the reported number of COVID-19 cases in India from mid-September 2020 points to a reduction in transmission, which could be attributed to higher seroprevalence in urban slum and non-slum areas, considering these locations to be the drivers of the epidemic in the country (Malani et al., 2021b). The findings of the third serosurvey also indicate that a large proportion of individuals in rural areas remain susceptible to SARS-CoV-2 infection. A similar finding was observed in the recent serosurvey conducted in Karnataka and Tamil Nadu (Malani et al., 2021a; Mohanan et al., 2021).

In India, several cities and states have conducted serosurveys. Metropolitan cities such as Delhi, Mumbai, Pune, Chennai, Ahmedabad and Hyderabad have reported seroprevalence ranging between 17.6% and 56% at different timepoints (see online Supplementary material). Tamil Nadu and Kerala conducted serosurveys covering all districts in October–November 2020 and February 2021, respectively. Seroprevalence reported in Chennai, Coimbatore and Tiruvannamalai districts of Tamil Nadu were comparable to the present survey. The higher seroprevalence in Palakkad, Ernakulam and Thrissur districts of Kerala found in the present survey compared with the Kerala serosurvey could be due to the use of assays for antibodies against the N-protein alone in the Kerala serosurvey.

Seroprevalence among HCWs (25.6%) observed in this study was much higher compared with the 8.7% prevalence estimated in a systematic review and meta-analysis among HCWs (Galakis et al., 2021).
Comparable seroprevalence among clinical, paramedical, field and administrative workers in health facilities and by place of contact with known COVID-19 case suggests widespread transmission of SARS-CoV-2 in the survey areas.

This study has several limitations. First, the participation of children aged 10–17 years in this survey was lower than the census-based age distribution in India (Office of the Registrar General and Census Commissioner, New Delhi and Government of India, 2011). According to the 2011 census, approximately 21% of the population were aged 10–17 years, whereas 8% of the study population were aged 10–17 years (see online Supplementary material). The under-representation of children and over-representation of adults in the survey could lead to underestimation of the true seroprevalence if one expects a real difference in the risk of exposure to SARS-CoV-2 across age groups. Further, 26% of the study clusters in the present survey were from urban areas, whereas, according to the 2011 census, 31% of the population of India reside in urban areas. Although the proportion of clusters from urban areas in this survey was slightly lower than the national average, this survey was representative of India overall. Approximately 18.5% of eligible individuals declined to participate in this survey. If this non-response was not at random, this could introduce selection bias. Second, different assays were used to measure IgG antibodies in the three serosurveys. In the first serosurvey, a laboratory assay which detected IgG antibodies against the whole cell antigen was used, and positive sera were retested with an assay which detected antibodies against the S1 domain of the S protein of SARS-CoV-2 (Murhekar et al., 2020). In the second serosurvey, a laboratory assay which detected IgG antibodies against the N protein of SARS-CoV-2 was used (Murhekar et al., 2021). As antibodies against the N protein of SARS-CoV-2 have been shown to decline faster over a period of time, the actual seroprevalence may have been under-estimated, and thereby the actual number of infections (Ripperger et al., 2020; Bolotin et al., 2021). In order to overcome these limitations, the serum samples were tested with both anti-N and anti-S1 assays in the third survey. Third, the infection to case ratio was estimated based on the reported number of cases of COVID-19. The completeness of reporting of COVID-19 cases could vary between Indian states.

In conclusion, the findings of the third nationwide serosurvey indicate that nearly one in four individuals aged ≥10 years from the general population as well as HCWs had been exposed to SARS-CoV-2 by December 2020 in India. Seroprevalence increased between August and December 2020, and the decline in the number of COVID-19 cases seen in India since mid-September could be on account of higher seroprevalence in urban areas. As three-quarters of the population are still susceptible, it is necessary to continue ongoing surveillance for COVID-19 cases, especially in rural areas. It is also necessary to continue implementation of non-pharmaceutical interventions, such as physical distancing, use of face masks and hand hygiene. The Government of India has initiated COVID-19 vaccination since January 2021, targeting healthcare and frontline workers in the first phase and individuals aged ≥60 years in the second phase (Ministry of Health and Family Welfare, Government of India, 2020). As a higher proportion of rural residents are susceptible to infection, and considering limited healthcare facilities in rural areas, especially oxygen beds (Kumar et al., 2020), elderly populations in rural areas may be prioritized for COVID-19 vaccination.

Author contributions
MVM, TB, JWVT, MSAK, KR, DCSR, SP and BB undertook the study design. TB, MSAK, JWVT, SSE, RSA, AT, SA, RB, SDB, AKB, VC, DD, AKD, KRD, GD, GRD, SMSK, MSKU, AL, MM, AMA, CR, JT, RY, RA, KA, DKB, PB, DB, JB, ASC, DC, AC, HD, SD, RD, DE, PG, IH, RKH, BJ, AK, SK, NNK, JSK, AK, NK, VGVK, GGJN, GM, NKM, AM, KN, AN, ARN, AKP, GVP, MAQ, SDR, AR, SSA, RS, KS, VKS, HBS, PKS, PS, RSI, NS, DSV, AV, VCW, SurY, SY, KZ, AC, AD, RSD, SD, RK, AMK, KN, SN, CP, KP, Sap, ShP, HR, TR, YKS and ShSh coordinated the field operations. CPGK coordinated the laboratory processing and testing of samples. VS, JWVT, MVM, RSA and MSAK performed data analysis. MVM, TB, JWVT, MSAK, KR, SP, DCSR and BB performed data interpretation. MVM, TB, VS, JWVT, RSA and MSAK accessed and verified the data. MVM, TB, MSAK and JWVT wrote the first draft of the manuscript. All authors approved the final version of the manuscript.

Conflict of interest
None declared.

Funding
This study was funded by the Indian Council of Medical Research.

Ethical approval
This study was approved by the Institutional Human Ethics Committee at ICMR National Institute of Epidemiology.

Acknowledgements
The authors acknowledge the field supervision and support provided by WHO India; the Ministry of Health and Family Welfare, Government of India; state and district health officials; and primary healthcare staff in the planning and conduct of the serosurvey. The authors thank the following team members from different Indian states.

Assam
Bibeck Saikia, Ritwik Dutta, Hridoy Ranjan Gogoi, Anshuman Saikia, Dipti Kangkana Kachari, Amir Sohail Khan, Mimal Nagtey, Jiturponi Saikia, Rimpi Konwar, Tikendra Gogoi, Prahlad Das, Parmananda Upadhyay, Pullab Das, Roojali Doley, Moon Saikia, Santanu Kakoty, Gamuk Kutum, Agastin Kerketa, Gunin Mili, Tapan Kalita, Krishna Khadka, Samir Ranjan Borah, Jiban Saikia, Pranjal Das, Amit Kumar Ray, Rituraj Borgohain, Mahanta Gogol, Bidya Pegu and Ananta Bora.

Bihar
Naveen Kumar Mandal, Kumar Gautam, Sanjeev Gupta, Ujjwal Prakash, Sahdeo Mandal, Prakash Ranjan, Saurav Kumar, Santosh Kumar, Rahul Kumar, Ranjeet Kumar, Paras Kumar, Kumar Rakesh Mandal, Satish Kumar Thakur, Amit Kumar, Amit Lakra, Ashish Kumar, Binod Kumar, Amit Ranjan, Prateek Raushan, Vikas Kumar, Muntaz Alam Khan, Baidyanath Roy, Alok Kumar, Ajeet Kumar Ram, Sakaldeep Kumar, Ajeet Kumar, Aaditya Panday, Umesh Kumar, Dhirendra Kumar, Abhay Kumar, Sanjeet Kumar, Bhoop Dhakar, Vikash Kumar Roy, Kudan Kunal, Vikash Kumar, Vivek Kumar, Amarendra Kumar, Vikram Kumar Chaudhary, Mohammad Arif, Raneeta Singh, Madhru Kumari, Roushan Kumar, Deen Dayal Kushwaha, Ashish Kumar B.P. Subramanya, Ujjwal Prasad Sinha, Rajeev Chandra Kumar, Ashish Tigga, Sanjay Kumar Singh, Geetika Shankar, Anand Gautam, Susheel Gautham, Rajendra Kumar, Ardash Varghese, Anisur Rehman Bhuiyan and Kunnal Kuvalekar.
Chhattisgarh

Archana Nagwanshi, Sunil Kumar Pankaj, Irsahdan Khan, Rahul Roy, Chetan Ravishankar Raut, Kunjibihari Patel, Chandra Kishore Thakre, Pekhan Kumar Sahu, Nand Kumar Modi, Nand Kumar Sahu, Champu Ratre, Bhooapeshtra Thakur, Awadh Baghel, Hemant Bawthande, Dev Kumar Sahu, Rajesh Kumar Soni, Devdas Joshi, Vokesh Yadu, Gulsahan Sahu, Cherapalli Rao, Manish A Prasad, and Keshav Dhruv.

Gujarat

Dinkar Raval, G.C. Patel, A.M. Kadri, Harsh N. Bakshi, Pranav G. Patel, Arthur Mcwan, Anand Santoke, Monark Vyas, S.A. Aarya, Pankaj Nimawat, Shabbir Ali Dedhrotiya, Vagalky Jani, Jitendra Patel, Hasmukh Parmar, Hardik Nakshiwala, Vaidheh Gohil, Jagdish Patel, Parulben Patel, Jigneshbhai Tavdi, Priyank Gandhi, Priyushbhai Parasar, Vinodbhai Valvi, Jagdishbhai Padvi, Dhawal Patel, Divyaben Zala, Mayurbhai Vasava, Mannitibhai Solanki, Darshaben Patel, Chetnabhai Chaudhari, Aartiben Rathva, Riyaben Mistry, Nikiben Bhai, Jyotibhai Bariya, Tejasbhai Patel, Kartikbhai Prajapati, Babita Roy, Pareshbhai Parmar, Manojbhai Bhagora, Pareshbhai Patel, Hemantbhai Kalasva, Sharadaben Vankar, Divya Patel, Ravishinh Chauhan, Nimisha Patel, Misha Patel, Harsha Sadat, Puja Patel, Girish Shah, Partapsinh Tavjaid, Rangibhai Gosai, Krutibhai Rana, Imtiyazbhai Shakh, Madhunben Mahera, Bhavikaben Patel, Prakashbhai Patel, Sangitaben Patel, Geetaben Patel, Pratapbhai Pagi, Bharathbhai Rana, Jinalbhai Patel, Archanaben Pandavi, Dilipbhai Bari, Ishavir Sinh Rathod, Sharmishtha Patel, Sunitbhai Solanki, Bhavesh Vaghela, Moimuddin Mansuri, Nitesh Rathod, Purvi Nayak, Hardeep Khair, Rajendra Acharya, Vijyaben Amin, Nirmal Prajapati, V.J. Pargi, Asmitaben Khareda, Rajubhai Patel, Komalaben, Hemangini Bari, Meenaben Bamaniya, Shantaben Prajapati, Rameshbhai Patel, Imran Mansuri, Vashvthbhai Nayak, K.K. Parmar, Rahul Siroli, Krunal Darji, Mahavir Solanki, Shivani Joshi and Mahesh Gavh.

Jammu and Kashmir

Haseena Mir, Syed Arshad Rafiq, Iqra Nisar Chowdri, Tanzeela Bashar Qazi, Rafiya Kousar, Irab Sabah, Shahroz Nabi, Abdul Aziz Lone, Ishiyaq Ahmad Sumji, Mehvish Afzal Khan, Shaista Ismail, Anjum Asma, Misbah Ferooz Kawoosa, Shifana Ayoub, Armaan Reyaz Kuchay, Saadatul Manzar, Iflaf Rafiq, Umar Wani, Taher Zahoor Khan, Ayesha Ajaz, Masoor Gayas, Zuba Reyaz, Umar Bashar Ganafe, Nafiyah Gulzar, Shazia Haffiz, Raja Salim, Tuba Riaz, Iram Jan, Mudeer Ahmad, Aadamullah Bhat, Rizwana Mehmood, Sadaqat Nawaz, Zaraka Arshad, Zubair Khan, Rayeesa Riyaz, Sajad Rasool Kar, Naik Sarmad Bashir, S.A. Majeed, Fayaz Ahmad Wani, Milad Zahoor, Showkat Hussain Bhat, Mohammad Yusuf Rather, Syed Bilal, Qazi Tufail, Afik Manzoor, Chulum Mohiuddin, Shabir Ahmad Dar, Feroz Ahmad, Riyaz Ahmad, Shaniqal Singh, Satnam Singh, Masrat Jan, Mushtaq Ahmad and Bilquees Akhtar.

Jharkhand

Anushil Anand, Swagata Lakshmi Tarafdar, Aloj Kumar, Aman Gupta, Vikash Kumar Sinha, Mukes Kumar Aggarwal, Vireesh Kumar Mishra, Nilesh Kumar, Abdul Kalam Azad, Raushan Raj, Mamta Kumari, Puja Kachhap, Soni Khatun, Sudhanshu Munda, Jayaram Mehta, Suraj Mahto, Jyoti Anant, Pratima Kumari, Ajay Kerkerda and Sony Khatun.

Karnataka

Jawaid Akhtar, Pankaj Kumar Pandey, Arundathi Chandrashekar, Patil Om Prakash, Rameshchandra Reddy, Naveen Madhavaiyan, K Sarika Jain Agrawal, N. Manohar, H.P. Arundathi Das, R. Ranganath, Vivekanand Reddy, Shazia Anjum, G. Hamsaveni, Lokesh Alahari, R.R. Sreedhar, K.R. Nischit, Swathi S Aithal, Mishra Hani, Anil Talikoti, N.T. Nagraj, Satish Ghatate, Shoba Rangswamy, C. Sandeep Reddy, Ravi Shankar, Savitha Rajesh, S. Sujatha Sriridh, Govardhan Gopal, Babu Mahendra, Vinay Kumar, Harish Raj, S. Vishwa, G. Srinivas, P. Premasudha, E.M. Vanitha, M.K. Suhail, H.R. Rakesh, S.R. Sahana, S. Sunitha, Mohammad Mustapa, M. Krishnamurthy, P.K. Rekha, Minaz-ul-Islam, Manohar Karnal, Sanjeev Patil, K. Archana, Amir Pasha, Renuka Katti, Mantappa Halamalli, Sunil Serikar, Siddhu Patil, N. Nagendra, Anand Babu, N.K. Hemath Kumar, O. Srinivasan, H.T. Mangala Gowri, Manjunath G. Achari, K.H. Raghunandan, M.T. Ravikumara, Y.G. Srikanta, Neelakantaayyaswamy I Hiremath, R. Hariprasanth, M.N. Prasanna, B. Dinesh Kumar, Praveen Pujar, Ullera Ashoka, A.N. Sunil, Umar Farooq M. Dalalavi, N. Narasimharaju, Bheema Zakheer Hussain, Namewar Hanmanth, M. Manjunatha, Venkatesh A Millattani, V.Sarath Kumar, M. Deepak, R. Sundara Murthi, H.S. Charan Raj Rao, J. Geetha, T.N. Basavaraju, B. Sampath and T.G. Gangadharaih.

Kerala

P.S. Rakesh, Suja Aloysius, A.K. Anitha, Sharath G. Rao, Nikilesh Menon Ravikumar, Arun Raj, Akhilada Pradeep, M.R. Abharami, A. Shilina, T. Nikhilamol, S. Anumol Raju, A.S. Asitha, M. Manoj, R. Sindhya, Neethu Sugathan, K. Sumi, Peneeva Varghes, A.L. Aravind Krishnan, M.P. Anupraman, V. Prakash Jaison, B.S. Vishnu Raj, V.S. Venoth, J. Gladson, M. Aravind Babu, D. Refic, A.R. Arima and Soniya Venu.

Maharashtra

G.S. Ganga, Dilip Sharma, Savita Bahekar, Archana Gaikwad, Namrata Haji, Hema Vishwakarma, Rahul Arke, Vivek Yengade, Vinod Pethkar, Pravin Dandge, Avinash Shinde, Diraj Prataptil, Aditya Bengale, Padmakar Kendre, Suraj Rakhunde, Prathamesh Chavan, Pramod Jamale, Anil Rathod, Akshay Phulari, Inayat Nadaf, Tejas Phale, Sunil Shirke, Ajit Buchude, Sourabhe Tidabe, Kartik Chittrakar, Ganesh Barate, Somnath Bangar, Kirtiraj Madanakar, Sagar Rokade, N. Ramaswami, Satish Pawar, Archana Patil, Pradeep Awate, Abhijeet Raut, Deepak Madhukar Mugaliak, Vipin Itankar, Rajendra Bhosale, Rahul Raghawar, Abhijeet Chaudhari, Rajesh Deshmukh, Nagurao S. Chavan, Balasaheb Nagargoje, Niklanth Bhosikar, Suryankant Gite, Sunil Pokhara, Sanjay Salunke, Dilip Patode, Shankar Rao Deshmukh, Balaji Shinde, Radhakrishna Pawar, Sandip Sangale, Milind Pore, Sandip Bhar武汉市, Rajabha Yeole, Rahul Shimp, Vikas Kokare, Chetan Khade, Harshad Lande, Avinash Borkar, Mohammad Abdul Haleem Azhar, Mujeeb Sayed and Amol Gaikwad.

Madhya Pradesh

M.P. Sharma, Shivendra Mishra, A.S. Malviya Mahavir Khandelwal, Devendra Bhothwal, C.K. Gupta, Seema Jaiswal, Jyoti Ahirwar, Ganesh Damor, Hemant Singh Thakur, Pratipal Singh, Hemant Pancheshwar, Bhagwansingh Patil, Rameshwar Utkay, Sheetal Saryami, Akashka Kushram, Shashibhushan Dubey, Sandip Sharma, Saurabh Bhadoriya, Himmat Singh, Yogendra Mourya, Shashank Kesharwani, Prahlad Soni, Pushpendra Rajput, Anikta Sharma, Ashish Namdeo, Jitendra Kumar, Priyanka Birha, Monu Sen, Rekha Prajapati, Priyanka Singore, Lipi Jain, Ashok Solanki and Kalpana Patel.

Odisha

Asit Mansingh, Shakti Ranjan Barik, Siba Prasad Mallik, Prashant Majhi, Deepak Sahoo, Partha Sarathi Patra, A.K. Bishoyee,
Hitesh Kumar Jain, Indurani Sagat, Santosh Kumar Sahoo, Rajesh Panda, Santosh Kumar Beuria, Sidhartha Kar, Soumya Panda, K. Sahu, Matrjuyoti Pattnaik, Dasarath Majhi, Biren Kumar Padhi, Padmamohan Pradhan and Arun Padhi.

**Rajasthan**

P.K. Anand, S.S. Mohanty, Ramesh Kumar Sangwan, Mohendra Thakor, Anil Purohit, Pankaj Kumar, Trilok Kumar, Bhawar Manohar, Sharwan Kumar, Jogaram Choudhary, Praveen Bhaghel, Suresh Kumar, Sandeep Kumar Yadav, Sunil Kumar, Mohan Lal Meena, Sunil Kumar, Arjun Singh and Mahaveer Singh.

**Tamil Nadu**

Y. John Arokyadoss, P. Kumaravel, A. Vasudevan, Magesh Kumar, J. Chitra, S. Jagannathan, Santhana Kumar, Sadham Hussain, Rajamani Sentrany, Kuppasamy Chandrabalu, Chandra Kumar, Lal Kumar, Selvam Suresh, Nandha Kumar, Muthu Murugesan, Kanjithi Kumar, Hari Vignesh, Devanga Akshitha, Dhanagopal Rajmohan, G. Preethi, Melveetili Kishor Sumitha, Rajendran Udhayakumar, Chandrasekar Tamil Mani Devi, Thanappan Selvendran, Suryakumar-ayanan Santhosh, Annadurai Arjun, Murugesan Balakrishnan, Vel Thamizharasan, Sharan Kumar Advath, Sahaya Mary Liza, Krishna Yadav Kattagoni, Thavamurugan Murugakaleswaran, Suresh Manickam, Govindaraj Senbagavalli and M. Thirumalai.

**Telangana**

M. Ananthan, Anwar Basha, P.P.S. Blessy, J.P. Deva Raj, S. Devindra, Mahesh Kumar, L. Meshram, Paras Sharma, Raja Sriswan, P. Raghavendra, G. Sarika, Santosh Kumar Banjara, J. Srinivas Rao, F. Sylivia, S. Sameera, Rajender Rao, A. Rajesham, B. Jagdish, R. Rajyalaxmi, Raji Reddy, N. Jhansi, B. Tulja, Venkata Ramana, B.V. Nancharamma, Hrusikesha Panda, G.L. Stephen, P. Sreenu, G. Bhavani, V. Aruna, Sree Ramakrishna, D. Narasimhulu, V. Chandrababu, G. Neeraja, Sheela Srinivas, T. Usha, K. Satyanarayana, S.P.V. Prasad, P. Sunu, Ch Anitha, D. Rani, Sai Babu, G. Vijaya Lakshmi, D. Swaroopa, G. Tulusi, Raghnadh Babu, D. Sreenu, Deepak Kumar, A. Bhagya Sri, Srethika Narayana, Kasu Kumari, Nasar Vali, N. Anjaiya, P. Venkatamma, B. Praveen, K. Madhu, G. Subba Rao, P. Sathiaiah and P. Nagender.

**Uttar Pradesh**

Akhileshwar Sharda, Sanidhya Bhargva, Dilip Singh, Vijay Kumar, Naresh Dhakar, Vinay Kumar, Akash Yadav, Deshdeepak Gautam, Swati Singh, Brijesh Maurya, Shaurab Kumar, Manisha Dhakar, Sheena Singh, Nitesh Kumar, Renu Kanwar, Rahul Yadav, Narendra Yadav, Rahul Kumar, Himalaya Kumar, Raju, Baljeet Sodhi, Rajesh Jain, Shivanka Gaur, Deepak Ohari, Tikam Singh, Subhagya Prakash, Haridutt Nemi, Dechen Yangdol, Upendra Singh, Harshit Kumar, Amit Yadav, Mohit Tiwari, Gopal Prasad, Sapna Yadav, Basudev Singh, Deepak Babu, Rahul Kumar, Chakrapani Kata, Chandra Pratap Singh, Simran Kaur Bhojwani, Manish Kumar, P. Vedula, Rahul Gond, Prabhat Kumar, Hariom Kushwah, Gani Aftridi, Nistha Verma, Veer Vishal, Rakesh Sharma, K. Uday, Saurabha Yadav, Navneet Rajput, Satyak Prakash, Mohit Sharma, Sunny Sharma, Santosh Kushwah, Akhlesh Yadav, Shimala Rathore, Prabha Shyakya, Vikas Sabharwal, Ravinder Singh, Sushil Chander, Manoj Sharma, Ramesh Kumar, Sukhwant Singh, Satyprat Vaidya, Raman Sharma, Pankaj Singh, Manu Jain, Archana Srivastava, Manoj Bahukhandi, Ashish Gusain, Arjuit Kumar, Dhruv Gopal, V. Mehta, Vineet Kumar Shukla, R.K. Gautam, Anil Gautam, J. S. Rawat, Bhuupinder Singh, Himanshu Sharma, Madhu Kumari, Rajesh Mourya, R.S. Yadav, Surinder Singh, Agam Jain, Raju Kumavat, Sandeep Patil, Pradhumn Katar, Namrata Soni, Prashant Upadhyaya, Praveen Pachauri, Ajay Rawat, Sanjay Chopra, Jyoti Mishra, Mohammad Husain, Debi Lal, Amit Mohan Prasad, Ghanshyam Singh, Atul Kumar Singhal, Ajay Singh Gautam, Vinay Dange, Shri Prakash Agrawal, Satish Chandra Singh, Birendra Panchal, Vishal Yadav, Mukesh Kumar Mishra, Ravi Shankar Singh, Kamlesh Sah, Sonal Rajput, Sushil Pal, Jairiddhan Siddharth, Ravi Nishad, Rohit Baghel, Punit Kumar, Abhishek Kumar Mishra, Avdhesh Kumar, Anu Gunj, Pawan Kumar, Anurag Srivastava, Virup Kumar, Kiran, Akash Kushwaha, Vinod Kumar, Ram Poojan Yadav, Mayank Badola and Santhosh Gupta.

**West Bengal**

Falguni Deb Nath, Suman Kanungo, Gargi Dutta Bhattacharyya, Subrata Biswas, Ajay Chakraborty, Jayesh Mehta, Bandita Sengupta, Abhijit Dey, Arup Chakraborty, Subhendu Kumar Roy, Subhadip Bhunia, Amlan Datta, Debasis Roy, Shyamal Soren, Jagannath Sarkar, Somnath Mukherjee, Prakash Chandra Midha, Girish Chandra Bera, Nitai Mandal, Santanu Sahu, Aatriye Chakraborty, Rabilu Islam Gayen, Dilip Biswas, Samudra Sengupta, Barnaman Tudu, Poulami Sen, Anjan Kumar Mallick, Saptarshi Bannerjee, Biswadeep Sengupta, Soumen Jana, Jayeeta Bhattacharaya, Medhavi Manish, Biswajit Namasharma, Chandan Ghosh, Debarati Chakraborty, Kumar Maity, Milan Barmann, Pintu Manik, Priya Rana, Purnima Roy, Rajani Kurmi, Rocky Ansari, Sanglap Maity, Somnobot Naskar, Souptik Jana, Sourav Pradhan, Bhaskha Pramanik, Dipanjali Sardar, Sujit Kumar Shrestha, Arpita Das, Shrikanth Shankar Gaiwal, Sriparna Garai, Swarnendu Sasmal, Ujjal Maity, Saiful Gazi, Joydeep Banerjee, Rupali Ghosh, Nawaid Ali, Pokhraj Dey, Chandan Ghosh, Susanta Bera, S.K. Monirul Jaman, Shrija Ghosh, Dev Kumar Dolai, Purnima Das, Wasim Reza and Rajesh Das.

**Appendix A. Supplementary data**

Supplementary material related to this article can be found, in the online version, at: doi:https://doi.org/10.1016/j.ijid.2021.05.040.

**References**

Bolotin S, Tran V, Osman S, Brown KA, Buchan SA, Jho E, et al. SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline. J Infect Dis 2021;223:1334–8.

Center for Devices and Radiological Health. EUA authorized serology testing service. Performance. Silver Spring, MD: FDA; 2021.

Chen X, Chen Z, Azman AS, Deng X, Sun R, Zhao Z, et al. Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis. Lancet Glob Health 2020;8:e598–609.

FETP Network – Chennai, India. COVID-19 Resource Center, Epicurve by state. FETP Network India; 2021 Available at: http://covidindiapdates.in/epicurve_state.php. [Accessed 19 February 2021].

Galainis P, Yraka I, Fragkou D, Bilali A, Kaitelidou D. Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis. J Hosp Infect 2021;108:120–34.

ICMR COVID Study Group. Laboratory surveillance for SARS-CoV-2 in India: performance of testing and descriptive epidemiology of detected COVID-19. January 22–April 30, 2020. Indian J Med Res 2020;151:424–37.

Indian Council of Medical Research. National ethical guidelines for biomedical and health research involving human participants. New Delhi: ICMR; 2017.

Irshad C, Eggre AE, Prokop W, Nairz M, Loacker L, Sahmic S, et al. Evaluation of four commercial, fully automated SARS-CoV-2 antibody tests suggests a revision of the Siemens SARS-CoV-2 IgG assay. Clin Chem Lab Med 2021;59:1143–54.

Kumar A, Rajasekharan Nayar K, Koya SF. COVID-19: challenges and its consequences for rural health care in India, Publ Health Pract 2020;1:100009. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 2020:26:845–8.

Malani A, Ramachandran S, Tandel V, Parasa R, Imad S, Siddharshini S, et al. SARS-CoV-2 seroprevalence in Tamil Nadu in October–November 2020. MedBioiv 2021a;2021.02.03.21250049.

Malani A, Shah D, Kang G, Lobo GN, Shastri J, Mohanan M, et al. Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India. Lancet Glob Health 2021b;9:e110–1.
McAndrews KM, Dowlatshahi DP, Dai J, Becker LM, Hessel J, Snowden LM, et al. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. JCI Insight 2020;5(2):e142386.

Ministry of Health and Family Welfare, Government of India. COVID-19 vaccines: operational guidelines. New Delhi: MHW; 2020.

Ministry of Home Affairs, Government of India. Guidelines for phased re-opening (Unlock 1). As per the Ministry of Home Affairs Order No. 40-3/2020-DM-1 (A) dated 30th May, 2020. New Delhi: MHA; 2020.

Mohanani M, Malani A, Krishnan K, Acharya A. Prevalence of SARS-CoV-2 in Karnataka, India. JAMA 2021;325:1001–3.

Murhekar MV, Bhatnagar T, Selvaraju S, Rade K, Saravanakumar V, Vivian Thangaraj JW, et al. Prevalence of SARS-CoV-2 infection in India: findings from the national serosurvey, May–June 2020. Indian J Med Res 2020;152:48–60.

Murhekar MV, Bhatnagar T, Selvaraju S, Saravanakumar V, Thangaraj JWV, Shah N, et al. SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey. Lancet Glob Health 2021;9:e257–68.

Office of the Registrar General and Census Commissioner, New Delhi and Government of India. 2011 census: age structure and marital status. Office of the Registrar General and Census Commissioner, Government of India; 2011.

Ozçüerümez MK, Ambrosch A, Frey O, Haselmann V, Holdenrieder S, Kiehntopf M, et al. SARS-CoV-2 antibody testing-questions to be asked. J Allergy Clin Immunol 2020;146:33–42.

Piccoli L, Ferrari P, Piumatti G, Jovic S, Rodriguez BF, Mele F, et al. Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland. Lancet Region Health Europe 2021;1:100013.

Rikhtegaran Tehrani Z, Saadat S, Saleh E, Ouyang X, Constantine N, Devico AL, et al. Performance of nucleocapsid and spike-based SARS-CoV-2 serologic assays. PLoS One 2020;15:e0237828.

Ripperger TJ, Uhrlaub JL, Watanabe M, Wong R, Castaneda Y, Pizzato HA, et al. Orthogonal SARS-CoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable humoral immunity. Immunity 2020;53:925–933.e4.

Sempos CT, Tian L. Adjusting coronavirus prevalence estimates for laboratory test kit error. Am J Epidemiol 2021;190:109–15.

Tol S, Mögling R, Li W, Godeke G-J, Swart A, Bergmans B, et al. Accurate serology for SARS-CoV-2 and common human coronaviruses using a multiplex approach. Emerg Microbes Infect 2020;9:1965–73.

World Health Organization. Population-based age-stratified seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) infection, 25 May 2020. Version 2.0. Geneva: WHO; 2020.

World Health Organization. Weekly epidemiological update – 5 January 2021. Geneva: WHO; 2020 Available at: https://www.who.int/publications/m/item/weekly-epidemiological-update--5-january-2021. [Accessed 12 May 2021].